Pluristem Therapeutics (PSTI) - Positive trends in radiation treatment

14:44 EDT 20 Jun 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Pluristem Therapeutics: Pluristem reported data from its pilot study of PLX-R18 for the treatment of acute radiation syndrome (ARS). The study included 48 non-human primates (NHP) who were dosed with 4m, 10m, and 20m cells per kg and showed an improvement in survival to 83%, 86% and 67%, respectively, from 50% in the control arm, although the study was not powered to significance. The company will need to perform a pivotal primate study and a human safety study for approval, which we expect in 2019-20.
ISIN: US72940R1023

Original Article: Pluristem Therapeutics (PSTI) - Positive trends in radiation treatment


More From BioPortfolio on "Pluristem Therapeutics (PSTI) - Positive trends in radiation treatment"

Quick Search


Relevant Topic

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...